Dr. Mohammed Siddique Rassool
University of the Witwatersrand
Johannesburg, South Africa
News
Dr. Nyanda Elias Ntinginya
NIMR Mbeya Medical Research Centre
Mbeya, Tanzania
Executive Group Meets Face-to-Face in Amsterdam
As preparation for the teleconference that the PanACEA General Assembly will hold in June, the project’s Executive Group met in Amsterdam to discuss its plans, and upcoming deliverables and milestones on May 12th, 2017. The Executive Group met with representatives from Tanzania, South Africa, the UK, Germany, and the Netherlands. Collaborations, publications, and capacity development…
PanACEA II meets in Cape Town
On 7 and 8 March 2017, the PanACEA consortium had their kick-off meeting in the sunny Cape Town in South Africa. A staggering number of 73 people attended the first day of the meeting. Important topics were the trials in the first two work packages, and PanACEA’s governance. Furthermore, time was set out for several partners…
16.5 Million Euro for PanACEA II
Rob Aarnoutse, Leon van Halder, and Martin Boeree signing the PanACEA II Grant Agreement PanACEA II has been granted 16.5 million euro in their drug development programme to shorten and simplify treatment of tuberculosis. On February 24th 2017, the coordinating team from Radboudumc Nijmegen, Martin Boeree and Rob Aarnoutse, have signed the PanACEA Grant Agreement…
PanACEA in The Lancet Infectious Diseases
On October 26th, 2016 The Lancet Infectious Diseases published the most recent findings from the multi-arm, multi stage tuberculosis (MAMS-TB) trial of the PanACEA consortium. The MAMS-TB trial investigated four new potential regimens for the treatment of tuberculosis. Trial results show that the highest rifampicin dose tested (35 mg/kg) is safe and reduces the time…
First Session PanACEA II in Liverpool
The preparations for PanACEA II have been in full swing with a meeting of a large part of the consortium in Liverpool. On October 26th 2016, the international group of partners met again to share thoughts and ideas about the continuation of PanACEA. Several presentations were held, results were shared and organisational issues were discussed.…
PanACEA MAMS-TB-01 finds high-dose rifampicin may help shorten TB treatment
Press release – Nijmegen, Netherlands / Munich, Germany February 26th 2015: At the annual Conference on Retroviruses and Opportunistic Infections (CROI), PanACEA, the Pan-African Consortium for the Evaluation of Antituberculosis Antibiotics, presented the results of its most recent phase IIb study (MAMS-TB-01). The most exciting finding from the study is that high-dose rifampicin results in…
Read more PanACEA MAMS-TB-01 finds high-dose rifampicin may help shorten TB treatment
Final PanACEA I Meeting in Alpbach, Austria
On January 25 – 28 the final PanACEA I meeting was held in Alpbach, Austria. PanACEA members of 11 countries (Belgium, Gabon, Germany, Great Britain, Kenya, Mozambique South Africa, Tanzania, The Netherlands, Uganda, and Zambia) attended the meeting. The newest results of the clinical studies, master and PhD studies and capacity development updates were presented.…
PanACEA in “World TB Day 2014 – Reach the 3 Million”
On March 24, 2014, Michael Hoelscher (LMU) presented “Advances in New TB Drug Development”, Tim McHugh (UCL) “Approaches to Monitoring Therapy” and Patrick Phillips (MRC CTU) “Drug Resistance vs. Drug Sensitive Trials “ at the “World TB Day – Reach the 3 Million” in London (www.who.int/campaigns/tb-day/2014/en). This conference, which was a joint venture between University…
Read more PanACEA in “World TB Day 2014 – Reach the 3 Million”